

# **Drug Market Access & Pricing in Europe**

Payer Contracts, HTA process and Tender management

#### **TOPICS**

- · Reference Pricing in Europe
- Payer-Archetyping
- Market Access and Pricing in France, Italy, Spain, Germany and the UK
- Specialties with regard to ATMPs/ Gentherapeutics
- HTA process and the role of RWE in the HTA context

### YOUR SPEAKERS



Dr Thomas Ecker Ecker + Ecker GmbH and Accessus Health GmbH, Hamburg, GERMANY



Graham Foxon Ph.D. MBA Remap Consulting UK Ltd, Cheshire, GREAT BRITAIN



**Dr Alicia Gil**OMAKASE Consulting S.L.,
Barcelona, SPAIN



Fabio Kistner Simon-Kucher & Partners Strategy & Marketing Consultants GmbH, Munich, GERMANY



**Dr Entela Xoxi** Senior Scientific Advisor -Independent consultant

## Aims and objectives

Market access and pricing for drugs is complex and requires careful preparation for launch. Knowledge of the underlying health systems and the different, mutually influencing pricing systems in Europe is essential for it.

In our online seminar you will receive the most important information for successful market access in the EU4 countries and in the UK.

22 April 2024: Payer archetypes, Market Access and Pricing in France and the UK

23 April 2024: Market Access and Pricing in Spain, Germany and Italy

#### Who should attend?

This online seminar is aimed at specialists and executives in the healthcare industry who are involved in market access and pricing in Europe.

## **Benefits of participation**

By attending the seminar...

- you know about the most important differences and similarities with regard to market access in Europe.
- you have insights in key trends in pricing & market access in Europe.
- you know how to avoid pitfalls in regard to price-referencing.
- you will get practical tips for your work in Market Access & Pricing.
- you will benefit from the experience of our experts.

## YOUR SPEAKERS

### **Dr Thomas Ecker**

Ecker + Ecker GmbH and Accessus Health GmbH, Hamburg CEO

### Graham Foxon Ph.D. MBA

Remap Consulting UK Ltd, Cheshire Managing Director

## Dr Alicia Gil

OMAKASE Consulting S.L., Barcelona CEO

#### **Fabio Kistner**

Simon-Kucher & Partners Strategy & Marketing Consultants GmbH, Munich Manager

#### Dr Entela Xoxi

UNIVERSITÀ CATTOLICA del Sacro Cuore - Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS)

Lecturer with Collaboration Agreement for Research Projects and Senior Scientific Advisor - Independent consultant

## Day 1: 9:00 am - 3:00 pm

## Payer archetypes in Europe

Fabio Kistner

Main payer archetypes - similarities and differences

# Market Access & Pricing in France Graham Foxon

- Stakeholder in France
- HTA process and the role of RWE in the HTA context
- Pricing negociation with CEPS; Value based pricing approaches?
- Managed Access Entry Agreements & Patient Access Schemes; role of ATU
- Specialties with regard to ATMPs/ Gentherapeutics
- · Price, volume & revenues forecasting

## Market Access & Pricing in the UK

Graham Foxon, Fatima Chunara

- Stakeholder & Stakeholder mapping post Brexit
- Managed Access Entry Agreements & Patient Access Schemes
- · Role of RWE in the HTA context
- Specialties with regard to ATMPs/ Gentherapeutics/Orphan drugs
- Value based pricing approaches
- Price, volume & revenues

## Day 2: 9:00 am - 3:00 pm

## Market Access & Pricing in Spain

Dr. Alicia Gil

- Stakeholder in Spain
- HTA process and the role of RWE
- Negociation with SGCMPS
- · Patient Access Schemes
- Specialties with regard to ATMPs/ Gentherapeutics/Orphan drugs
- · Price, volume & revenues forecasting

## Market Access & Pricing in Italy

Dr. Entela Xoxi

- · Stakeholder in Italy
- Managed Access Entry Agreements & Patient Access Schemes
- · Role of RWE in the HTA context
- Specialties with regard to ATMPs/ Gentherapeutics/Orphan drugs
- Value based pricing approaches
- Price, volume & revenues

# Market Access & Pricing in Germany Dr. Thomas Ecker

- The AMNOG process 2023 role of RWE?
- Challenge AbDe
- Managed Access Entry Agreements & Patient Access Schemes - what is possible
- Price, volume & revenues: new requirements!
- Recent legal changes for price negotiations
- Value based pricing approaches
- Market Access and pricing for medical apps

## **Drug Market Access & Pricing in Europe**

#### **REGISTRATION UNDER**

service@forum-institut.com www.forum-institut.com Webcode 24042202 Tel. +49 6221 500-500 Fax +49 6221 500-555



#### **REGISTRATION FORM**

Yes, I will attend	<b>Date</b> 22 - 23 April 2024 - online 22 April 2024: 9:00 am - 3:00 pm 23 April 2024: 9:00 am - 3:00 pm
☐ Drug Market Access & Pricing in Europe	
☐ Yes, I agree that FORUM Institut may inform me about events by: ☐ email; and/or ☐ telephone. I may withdraw my consent at any time.	
	Fee  € 1590.00 (+ German VAT) The participation fee includes documentation for download, a certificate, access to the Learning Space and technical support including PreMeeting.
Name	
Position, department	Procedure of an online seminar Online seminars - live and interactive via the Learning Space. Your access data and all accompanying documents are accessible at any time in the Learning Space. Didactically and technically optimally concept with plenty of room for your questions. Free PreMeeting to prepare Continuous support during the online seminar for optimal learning success.
Company	
Street	
Post code, city, country	
Tel. no./Fax no.	
E-mail	to: optimal learning duoteds.
Contact person at office	
Date, signature	

#### **CANCELLATION POLICY**

Our general terms and conditions (as of 01 November 2021) apply and are available upon request. We can send them to you at any time. Alternatively, you can access them online at www.forum-institut.com/t&c





PharmaTrain

#### YOUR CONTACT



Leila Grupp Conference Manager Tel. +49 6221 500-695 I.grupp@forum-institut.de